The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial

European Urology

Volumn 44, Issue 4, 2003, Pages 423-428

  Sylvester, Richard J ^a   Van der Meijden, Adrian P M ^b   Oosterlinck, Wim ^c   Hoeltl, Wolfgang ^d   Bono, Aldo V ^e  

^a Treatment of Cancer Data Center   (Belgium)

^b JEROEN BOSCH HOSPITAL   (Netherlands)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d KAISER FRANZ JOSEF HOSPITAL   (Austria)

^e OSPEDALE DI CIRCOLO   (Italy)

Author keywords

Adverse effects; Bladder neoplasms; Efficacy; Mycobacterium bovis; Transitional cell carcinoma

Indexed keywords

BCG VACCINE; EPIRUBICIN; ISONIAZID;

ALLERGIC REACTION; ARTHRALGIA; ARTHRITIS; ARTICLE; BLADDER CARCINOMA; BLADDER DISEASE; CHILL; CLINICAL TRIAL; CONTRACTED BLADDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTITIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERANCE; EPIDIDYMITIS; FEVER; FLU LIKE SYNDROME; HEMATURIA; HUMAN; LIVER TOXICITY; LUNG INFECTION; MAJOR CLINICAL STUDY; MALAISE; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATITIS; RANDOMIZED CONTROLLED TRIAL; RASH; SEPSIS; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; URETER OBSTRUCTION; URINE CULTURE;

EID: 0141460506     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(03)00371-3     Document Type: Article

References (20)

1. Sylvester RJ, van der Meijden APM, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-70.
2. Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169:90-5.
3. Lamm DL, Steg A, Boccon-Gibod L, Morales A, Hanna Jr MG, Pagano F, et al. Complications of bacillus Calmette-Guerin immunotherapy: Review of 2602 patients and comparison of chemotherapy complications. Prog Clin Biol Res 1989;335-55.
4. Lamm DL, Blumenstein BA, Crawford DE, Montie JE, Scardino PA. A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette-Guérin for transitional cell carcinoma of the bladder. N Eng J Med 1991;325:1205-9.
5. Van der Meijden APM, Brausi M, Zambon V, Kirkels W, de Balincourt C, Sylvester R. Intravesical instillation of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder. A European Organization for Research and Treatment of Cancer GU Group randomized phase III trial. J Urol 2001;166:476-81.
6. Orihuela E, Herr HW, Pinsky CM, Whitmore WF. Toxicity of intravesical BCG and its management in patients with superficial bladder tumors. Cancer 1987;60:326-33.
7. Orihuela E, Herr HW. Correlation between intravesical (IV) BCG toxicity and tumor response in patients (pts) with superficial bladder cancer. J Urol 1990;143:341A [Abstract 612].
8. Luftenegger W, Ackermann DK, Futterlieb A, Kraft R, Minder CE, Nadelhaft P, et al. Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors. J Urol 1996;155:483-7.
9. Saint F, Patard JJ, Irani J, Salomon L, Hoznek A, Legrand P, et al. Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer. Urology 2001;57:617-21.
10. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, TI and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study. J Urol 2000;163:1124-9.
11. Vegt PFJ, van der Meijden APM, Sylvester R, Brausi M, Hoeltl W, de Balincourt C. Does Isoniazid reduce side effects of intravesical bacillus Calmette-Guérin therapy in superficial bladder cancer? Interim results of EORTC protocol 30911. J Urol 1997;157:1246-9.
12. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983;1:710-9.
13. Lamm DL, van der Meijden AP, Akaza H, Brendler C, Hedlund PO, Mizutani Y, et al. Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses? Int J Urol 1995;2(Suppl 2):23-35.
14. De Reijke TM, De Boer EC, Kurth KH, Schamhart DHJ. Urinary interleukin-2 monitoring during prolonged bacillus Calmette-Guerin treatment: can it predict the optimal number of instillations. J Urol 1999;161:67-71.
15. Kumar A, Dubey D, Bansal P, Mandhasi A, Naik S. Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus Calmette-Guerin (modified Danish 1331 strain) for superficial bladder cancer. J Urol 2002;168:2232-5.
16. Thalmann GN, Sermier A, Rentsch C, Mohrle K, Cecchini MG, Studer UE. Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J Urol 2000;164:2129-33.
17. Lamm DL. Bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol 1985;134:40-7.
18. Torrence RJ, Kavoussi LR, Catalona WJ, Ratliff TL. Prognostic factors in patients treated with intravesical bacillus Calmette-Guerin for superficial bladder cancer. J Urol 1988;139:941-4.
19. Kelley DR, Haaff EO, Becich M, Lage J, Bauer WC, Dresner SM, et al. Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guerin. J Urol 1986;135:268-71.
20. Saint F, Salomon L, Quintela R, Cicco A, Hoznek A, Abbou CC, et al. Do prognostic parameters of remission versus relapse after bacillus Calmette-Guerin immunotherapy exist? Analysis of a quarter century of literature. Eur Urol 2003;43:351-61.